MarketCap
Facebook
X
Telegram
SunLink Health Systems Financial Ratios 2024-2009 | SSY
Brief overview of SunLink Health Systems's market valuation
The comparison uses the five latest available annual observations between 2013 and 2021.
Market valuation is represented by P/E 1.24x (median 5.01x), EV/EBITDA 1.48x (median 4.3x), P/S 0.17x (median 0.17x). Ratios sit near their own comparison base, with an average deviation of -0.3% from five-year medians.
At the current P/E, inverse earnings yield is 80.4%, a useful bridge between price and business earnings.
Current measures of operating quality are ROE -9.6%, ROA -7.4%, ROCE -14.7%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
The cash conversion cycle decreased 12.3 days to 35.6 days, supporting working-capital efficiency.
Conclusion
SunLink Health Systems's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios SunLink Health Systems
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3.7 | -3.3 | -3.6 | 1.2 | -11.0 | -4.8 | -6.4 | 5.0 | 4.9 | -0.4 | 14.0 | 51.6 | 1.6 | -10.2 | - | - |
P/S |
0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | - | - |
EPS |
-0.2 | -0.3 | -0.3 | 1 | -0.2 | -0.2 | -0.2 | 0.3 | 0.3 | -1.0 | 0.1 | 0.0 | 0.4 | -0.1 | -0.2 | - |
EV (Enterprise Value) |
-1.54 M | 1.48 M | 359 K | -1.4 M | 15.6 M | 10.1 M | 15.8 M | 16.6 M | 37.2 M | 21.1 M | 40.6 M | 43.5 M | 54.2 M | 60.4 M | -1.7 M | -2.36 M |
EBITDA per Share |
-0.15 | 0.19 | -0.55 | 0.47 | 0.16 | -0.08 | 0.09 | -0.27 | -0.43 | 0.52 | 0.5 | 0.23 | 0.69 | -1.33 | 1.06 | - |
EV/EBITDA |
1.5 | 1.1 | -0.1 | -0.4 | 13.9 | -17.2 | 21.2 | -6.6 | -9.1 | 4.3 | 8.6 | 19.8 | 8.3 | -4.8 | -0.2 | - |
PEG |
0.03 | 0.03 | 0.03 | -0.01 | 0.07 | 0.04 | 0.14 | -0.15 | -0.09 | 0.01 | 0.18 | 0.01 | 0.09 | 0.0 | - | - |
P/B |
0.3 | 0.3 | 0.3 | 0.3 | 0.9 | 0.6 | 0.6 | 0.6 | 0.8 | 0.1 | 0.4 | 0.3 | 0.2 | 0.3 | - | - |
P/CF |
-1.9 | -11.0 | -1788.3 | 6.3 | 3.2 | -5.9 | 25.9 | -2.4 | -35.5 | 1.2 | 3.5 | -5.8 | 2.1 | 2.0 | - | - |
ROE % |
-9.56 | -10.31 | -10.51 | 33.11 | -8.30 | -11.66 | -9.27 | 12.39 | 15.90 | -27.85 | 2.93 | 0.67 | 13.43 | -3.60 | -4.14 | - |
ROA % |
-7.41 | -7.71 | -7.19 | 21.83 | -4.08 | -7.18 | -6.09 | 7.61 | 7.02 | -16.36 | 1.53 | 0.33 | 4.97 | -1.02 | -1.92 | - |
ROCE % |
-14.70 | 0.40 | -26.37 | 8.54 | -1.99 | -14.45 | -5.21 | -19.59 | -27.12 | 4.79 | 2.20 | -4.06 | 4.55 | -29.66 | 5.76 | - |
Current Ratio |
- | - | - | - | 2.0 | 2.6 | 2.9 | 2.6 | 1.7 | 2.4 | 2.1 | 2.0 | 1.6 | 1.6 | - | - |
DSO |
33.5 | 38.4 | 38.9 | 38.1 | 34.5 | 38.2 | 43.3 | 41.3 | 39.8 | 34.8 | 34.8 | 38.9 | 43.7 | 22.3 | - | - |
DIO |
31.8 | 33.2 | 34.9 | 49.7 | 36.2 | 36.8 | 39.5 | 37.2 | 34.1 | 37.5 | 42.1 | 30.9 | 28.9 | 14.9 | - | - |
DPO |
29.7 | 23.7 | 23.5 | 26.0 | 22.7 | 26.7 | 27.7 | 38.7 | 36.0 | 39.2 | 55.7 | 50.0 | 50.6 | 25.6 | - | - |
Operating Cycle |
65.3 | 71.6 | 73.8 | 87.8 | 70.7 | 75.0 | 82.8 | 78.6 | 74.0 | 72.3 | 76.9 | 69.8 | 72.6 | 37.2 | - | - |
Cash Conversion Cycle |
35.6 | 47.9 | 50.4 | 61.8 | 48.0 | 48.3 | 55.2 | 39.9 | 37.9 | 33.1 | 21.1 | 19.9 | 22.1 | 11.6 | - | - |
All numbers in USD currency
Quarterly Financial Ratios SunLink Health Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.09 | -0.15 | -0.09 | -0.15 | -0.08 | - | -0.12 | -0.06 | -0.19 | - | -0.11 | 0.28 | -0.22 | 0.06 | -0.13 | -0.09 | 0.28 | 0.19 | -0.08 | 0.45 | -0.05 | 0.45 | -0.05 | -0.01 | -0.04 | -0.01 | -0.04 | 0.04 | -0.12 | 0.04 | -0.12 | 0.08 | -0.03 | 0.08 | -0.03 | 0.33 | 0.32 | 0.33 | 0.32 | -0.99 | -0.18 | -0.99 | -0.18 | 0.1 | -0.04 | 0.1 | -0.04 | 0.02 | -0.12 | 0.02 | -0.12 | 0.42 | -0.15 | 0.42 | -0.15 | -0.1 | -0.18 | -0.1 | -0.18 |
EBITDA per Share |
-0.05 | -0.1 | -0.05 | -0.1 | -0.13 | - | -0.07 | -0.02 | -0.02 | - | -21.5 | 364 | -0.05 | 0.17 | -0.1 | -0.1 | -0.1 | -0.2 | -0.03 | 0.01 | - | 0.01 | - | 0.09 | 0.02 | 0.09 | 0.02 | 0.03 | -0.05 | 0.05 | -0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | -0.05 | 0.05 | -0.05 | -0.09 | -0.08 | -0.13 | -0.12 | 0.28 | 0.11 | 0.34 | 0.07 | 0.11 | - | 0.08 | - | - | -0.16 | - | -0.16 | 0.01 | -0.05 | -0.06 | -0.08 |
ROE % |
-29.08 | -27.64 | -30.13 | -48.77 | -47.59 | -44.03 | -48.08 | -26.08 | -11.29 | -2.93 | -0.87 | -1.48 | -14.13 | 3.24 | 7.66 | 8.99 | 30.32 | 40.45 | 52.64 | 53.43 | 34.49 | 14.07 | -4.87 | -4.09 | -1.93 | -5.56 | -3.51 | -6.86 | -4.96 | -0.86 | 0.71 | 4.56 | 12.85 | 27.54 | 40.09 | 56.88 | 3.43 | -15.20 | -58.94 | -79.42 | -35.16 | -31.19 | -0.41 | 3.26 | 1.07 | -1.22 | -3.48 | -5.62 | 6.04 | 4.49 | 17.25 | 14.84 | -1.65 | -3.15 | -19.52 | -18.33 | -6.61 | -2.93 | -4.65 |
ROA % |
-22.71 | -21.67 | -22.80 | -35.33 | -34.00 | -31.20 | -34.32 | -17.69 | -7.13 | -0.94 | 0.47 | 0.28 | -9.69 | 1.93 | 4.79 | 6.20 | 18.96 | 24.03 | 30.55 | 31.23 | 20.27 | 8.25 | -2.72 | -2.52 | -1.15 | -3.43 | -2.06 | -4.47 | -3.13 | -0.49 | 0.86 | 3.50 | 8.59 | 16.81 | 21.90 | 30.11 | 2.04 | -8.41 | -36.48 | -46.93 | -24.85 | -22.48 | -0.40 | 1.97 | 0.67 | -0.44 | -1.74 | -2.79 | 1.94 | 1.66 | 6.30 | 6.20 | -0.02 | 0.11 | -6.01 | -6.08 | -1.91 | -1.14 | -1.87 |
ROCE % |
-23.85 | -26.53 | -26.49 | -24.80 | -20.45 | -12.88 | -15.25 | 2.81 | 2.69 | 5.38 | 7.49 | 5.12 | -10.53 | -11.39 | -22.93 | -21.02 | -17.73 | -15.24 | -7.12 | -6.29 | -3.27 | -2.92 | 0.18 | 0.78 | -1.60 | -3.85 | -5.82 | -7.98 | -7.65 | -4.51 | -4.68 | -1.56 | -1.13 | -4.32 | -3.85 | -7.39 | -12.02 | -11.55 | -15.50 | -15.33 | -6.50 | -2.70 | 5.41 | 9.04 | 5.32 | 2.70 | -1.98 | -3.71 | -6.46 | -9.66 | -11.31 | -15.29 | -15.29 | -13.17 | -12.10 | -7.43 | -3.04 | -0.99 | -1.20 |
DSO |
36.0 | 33.2 | 36.0 | 33.6 | 36.8 | - | 37.5 | 31.2 | 28.6 | - | 49.5 | 39.3 | 57.0 | 16.8 | 39.3 | 39.6 | 38.5 | 18.6 | 39.3 | 37.2 | 37.2 | 38.8 | 43.5 | 38.4 | 38.6 | 33.6 | 40.0 | 38.0 | 42.1 | 30.9 | 38.0 | 40.6 | 40.6 | 19.8 | 41.8 | 40.2 | 42.2 | 39.5 | 53.3 | 51.0 | 47.2 | 38.9 | 46.2 | 54.4 | 54.2 | 38.9 | 36.6 | 41.6 | 48.3 | 41.7 | 47.4 | 46.8 | 48.9 | 43.3 | 52.1 | 50.4 | 55.9 | 35.5 | - |
DIO |
60.5 | 50.7 | 60.5 | 52.1 | 46.0 | - | 54.3 | 54.6 | 56.3 | - | 64.6 | 67.2 | 64.9 | 16.7 | 36.7 | 36.3 | 37.0 | 18.4 | 42.0 | 42.0 | 39.9 | 40.3 | 40.8 | 38.1 | 37.2 | 37.9 | 36.9 | 38.1 | 9.3 | 9.2 | 31.0 | 33.8 | 34.6 | 33.5 | 34.1 | 35.5 | 38.5 | 41.4 | 48.9 | 42.9 | 38.1 | 30.7 | 33.5 | 35.4 | 33.5 | 33.5 | 28.3 | 33.0 | 26.8 | 27.1 | 27.1 | 26.8 | 27.0 | 26.5 | 28.3 | 30.4 | 31.7 | 27.0 | - |
DPO |
52.6 | 44.1 | 52.6 | 41.9 | 48.1 | - | 50.8 | 47.5 | 42.3 | - | 61.8 | 68.2 | 57.5 | 12.3 | 24.2 | 27.2 | 27.1 | 11.8 | 29.8 | 32.5 | 25.9 | 18.8 | 26.2 | 30.1 | 29.0 | 29.4 | 28.7 | 29.2 | 6.6 | 6.1 | 23.1 | 28.4 | 27.4 | 24.4 | 32.1 | 36.8 | 43.3 | 53.7 | 63.1 | 52.8 | 39.3 | 31.8 | 42.4 | 44.1 | 39.3 | 39.0 | 36.9 | 47.7 | 38.1 | 39.1 | 48.8 | 52.9 | 48.5 | 47.3 | 51.0 | 52.5 | 52.8 | 43.4 | - |
Operating Cycle |
- | - | 96.5 | 85.7 | 82.7 | - | 91.8 | 85.9 | 84.9 | - | 114.0 | 106.5 | 121.9 | 33.5 | 76.0 | 76.0 | 75.5 | 37.0 | 81.3 | 79.2 | 77.1 | 79.1 | 84.3 | 76.4 | 75.8 | 71.5 | 76.9 | 76.1 | 51.4 | 40.2 | 69.0 | 74.3 | 75.2 | 53.2 | 75.9 | 75.6 | 80.7 | 80.9 | 102.1 | 93.9 | 85.4 | 69.7 | 79.7 | 89.8 | 87.7 | 72.3 | 64.9 | 74.7 | 75.1 | 68.8 | 74.5 | 73.6 | 76.0 | 69.8 | 80.4 | 80.9 | 87.7 | 62.5 | - |
Cash Conversion Cycle |
- | - | 43.8 | 43.9 | 34.6 | - | 41.0 | 38.4 | 42.6 | - | 52.2 | 38.3 | 64.5 | 21.2 | 51.8 | 48.7 | 48.3 | 25.3 | 51.5 | 46.7 | 51.2 | 60.2 | 58.1 | 46.3 | 46.8 | 42.1 | 48.2 | 46.9 | 44.8 | 34.1 | 46.0 | 46.0 | 47.7 | 28.9 | 43.8 | 38.8 | 37.4 | 27.1 | 39.0 | 41.1 | 46.1 | 37.9 | 37.3 | 45.7 | 48.4 | 33.3 | 28.0 | 27.0 | 37.0 | 29.7 | 25.8 | 20.8 | 27.5 | 22.6 | 29.4 | 28.4 | 34.9 | 19.1 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company SunLink Health Systems, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
China
USA
Russia
Germany
Britain
